EDMUND C. KING - Corporate Board Profile

LTC PROPERTIES INC

Filing Date	Source Excerpt
2003-06-26	During 2002, the Audit Committee was comprised of Mr. Yellen, Chair, Mr. King and Dr. Triche. The Nominating and Governance Committee was comprised of Dr. Triche, Chair, Mr. King and Mr. Yellen. The Compensation Committee was comprised of Mr. King, Chair, Dr. Triche and Mr. Yellen. Primarily in 2002 each non-employee director received a fee of $10,000 per year for services as a director plus $500 for attendance in person at each meeting of the Board of Directors or of any committee meeting held on a day on which the Board of Directors does not meet.
2004-04-15	Edmund C. King is a general partner of Trouver Capital Partners, an investment banking firm located in Los Angeles, California and Provo, Utah. Previously, Mr. King was Ernst & Young LLP's Southern California senior health care partner from 1973 through September 30, 1991. Mr. King is Chief Financial Officer and a director of Invisa, Inc.
2005-04-15	Edmund C. King is a general partner of Trouver Capital Partners, an investment banking firm located in Los Angeles, California and Provo, Utah. Previously, Mr. King was Ernst & Young LLP's Southern California senior health care partner from 1973 through September 30, 1991. Mr. King is Chief Financial Officer and a director of Invisa, Inc.
2006-03-31	Edmund C. King is the principal owner of Trouver Capital Partners, an investment banking firm located in Los Angeles, California and Provo, Utah. He is Chair of the Audit Committee. Annual director fees include $6,250 per quarter and $750 per meeting. No specific total compensation stated, estimated from fees.
2007-04-09	Edmund C. King is the principal owner of Trouver Capital Partners, an investment banking firm located in Los Angeles, California and Provo, Utah. Previously, Mr. King was Ernst & Young LLP's Southern California senior health care partner from 1973 through September 30, 1991. Mr. King is Chief Financial Officer and a director of Invisa, Inc. He also serves on the Board of Directors of Accentia Biopharmaceuticals, Inc., a publicly-traded biopharmaceutical company.
2008-04-29	Edmund C. King is the principal owner of Trouver Capital Partners, an investment banking firm located in Los Angeles, California and Provo, Utah. Mr. King has been the principal owner of Trouver Capital Partners since 1997. Previously, Mr. King was Ernst & Young LLP's Southern California senior health care partner from 1973 through September 30, 1991. Mr. King is President, Chief Financial Officer and a director of Invisa, Inc. He also serves on the Board of Directors of Accentia Biopharmaceuticals, Inc., a publicly-traded biopharmaceutical company.
2009-04-09	Edmund C. King is the principal owner of Trouver Capital Partners, an investment banking firm located in Los Angeles, California and Provo, Utah. Mr. King has been the principal owner of Trouver Capital Partners since 1997. Previously, Mr. King was Ernst & Young LLP's Southern California senior health care partner from 1973 through September 1991. Mr. King is acting President, Chief Financial Officer and a director of Invisa, Inc. He also serves on the Board of Directors of Accentia Biopharmaceuticals, Inc., a publicly-traded biopharmaceutical company.
2010-04-22	Mr. King is the principal owner of Trouver Capital Partners, an investment banking firm located in Los Angeles, California and Provo, Utah. Mr. King has been the principal owner of Trouver Capital Partners since 1997. Previously, Mr. King was Ernst & Young LLP's Southern California senior health care partner from 1973 through September 1991.
2011-04-29	Mr. King has served as Chief Financial Officer and on the Board of Directors of Invisa, Inc., a publicly-held industrial instrument company, since February 2000, and serves as their Chief Executive Officer. He also has been the general partner of Trouver Capital Partners, an investment banking firm with locations in the Western United States, since 1997. Previously, Mr. King was Ernst & Young LLP's Southern California senior health care partner from 1973 through September 1991.
2012-04-20	Mr. King has served as Chief Financial Officer and on the Board of Directors of Invisa, Inc., a publicly-held industrial instrument company, since February 2000, and serves as their Chief Executive Officer. He also has been the general partner of Trouver Capital Partners, an investment banking firm with locations in the Western United States, since 1997. Previously, Mr. King was Ernst & Young LLP's Southern California senior health care partner from 1973 through September 1991. He is on the Board of Directors of Accentia Biopharmaceuticals, Inc. and its subsidiary Biovest International, Inc., both publicly-traded biopharmaceutical companies.
2013-04-19	Mr. King has served as Chief Financial Officer and on the Board of Directors of Invisa, Inc., a publicly-held industrial instrument company, since February 2000, and currently serves as their Chief Executive Officer. He also has been the general partner of Trouver Capital Partners, an investment banking firm with locations in the Western United States, since 1997. Previously, Mr. King was Ernst & Young LLP's Southern California senior health care partner from 1973 through September 1991. He is on the Board of Directors of Biovest International, Inc., a publicly-traded biopharmaceutical company.
2014-04-28	Mr. King has served as Chief Financial Officer and on the Board of Directors of Invisa, Inc. Mr. King's prior service as an independent director of LTC Properties, Inc., financial management background, history of working with public companies, knowledge of health care matters, and multi-decade experience with accounting-related reporting and controls led the Board to conclude he should be nominated to serve another term as director. Director Compensation for the Year ended December 31, 2013: Edmund C. King Fees Earned or Paid in Cash $52,300 Stock Awards $97,734 Total $150,034. The Board has determined that each member of the Compensation Committee is independent. Dr. Triche serves as Chairman of the Compensation Committee. The Nominating and Corporate Governance Committee is responsible for identifying, screening and reviewing individuals qualified to serve as directors. Mr. Pieczynski has served as Chairman of the Nominating and Corporate Governance Committee since April 2014. Previously since May 2013, Mr. King served as Chairman of the Nominating and Corporate Governance Committee.
2015-04-24	Edmund C. King: Fees Earned or Paid in Cash $53,928, Stock Awards $84,105, Total $138,033. Edmund C. King's term on the Board will expire directly after the 2015 Annual Meeting. He serves on Audit, Compensation, and Nominating and Corporate Governance Committees.